Gathering in the mountains and seas of South Guangdong, talking about the peptide world

In the midsummer, the Bay Area gathers together. From June 27th to 29th, the "Gathering in the Mountains and Seas to Write the GLP-1 Heroes" private meeting was successfully held in Shenzhen, Guangdong! More than 50 outstanding experts, entrepreneurs and investors in the field of GLP-1/peptide drugs gathered in Shenzhen Bay to discuss the development trends and future opportunities of the GLP-1 drug industry.

This private meeting was guided by the Peptide Innovation Alliance, hosted by the Peptide Research Society, supported by the Economic Development Promotion Center of Dongguan Binhaiwan New Area, and sponsored by Aij Boya.

Meeting friends on the boat

The boat is sailing on the blue waves, and people are swimming in the painting.

On the afternoon of June 27th, industry leaders gathered in Shekou Nanhai and boarded the boat to go out to sea. Five yachts set off from the Shenzhen Bay Bridge waters, passing through the Nei Lingding waters and Shekou Port. Shenzhen Bay is located between the northwest of the New Territories of Hong Kong, China and the western waters of Nanshan District, Shenzhen, Guangdong, China. It is located west of Yuen Long Plain and east of Shekou. It has a unique geographical location and is one of the shining landmarks of Shenzhen. The gentle sea breeze, carrying the voices of peptide practitioners, blows to the vast inland.

A Hundred Schools of Thought

Discuss the thoughts in your heart and discuss the matter of peptides.

On the morning of June 28, the Peptide Innovation Alliance was officially established under the witness of thirty peptide industry leaders. Five speakers shared their research results and insights on the development status and trends of GLP-1 around the four themes of "technology transformation", "upstream promotion", "bottom-level platform empowerment" and "innovation ecology". Nine units participated in the roadshow.

1. Peptide Innovation Alliance Established

Professor Wang Zhuyin, the leader of the Peptide Innovation Alliance and founder and chairman of Shenzhen Peptide Sheng Biological Company, delivered a speech, analyzing the current market size of peptide drugs, marketed drugs, clinical research and indications, and placed deep and beautiful expectations on the Chinese and global peptide drug markets.

Leader of the Peptide Innovation Alliance, Peptide Sheng Bio, Founder & Chairman Wang Zhuyin

Peptide Innovation Alliance was officially established

2. Keynote Speech

Professor Li Zigang, Director of Pingshan Biomedical R&D Transformation Center, took the topic of "Biomedical Applications of Stable Peptides" and explained that stable peptides can be used for covalent inhibitor development, peptide-coupled drug development, β-amyloid protein-related disease treatment, breast cancer inhibitor development, mitochondrial autophagy regulation and peptide nuclear medicine development, as well as peptide carriers for nucleic acid drug delivery and tumor immunotherapy.

Director of Pingshan Biomedical R&D Transformation Center Li Zigang

The theme of Dr. Wang Qunjie, CEO of Ajie Boya, was "Review and Prospect of the Development of Chromatography in China for Forty Years". He started by introducing the discovery and technological development of chromatography, and then proposed that industrial high-performance liquid chromatography purification in the 2020s can be applied to GLP-1, nucleic acid drugs and intermediates, ADC, vitamins and beauty peptides, etc., with a high-purity and large-scale development trend.

Wang Qunjie, CEO of Ajie Boya

Professor Wang Zhuyin, leader of the Peptide Innovation Alliance and founder and chairman of Peptide Sheng Bio, spoke on the topic of "High-throughput entity screening system for peptide molecular libraries", declaring that the wave of peptide innovative drug research and development has arrived, and my country's peptide innovative drugs need to carry out source innovation to remain invincible. In addition, Professor Wang introduced that the peptide library of Peptide Sheng Bio has the characteristics of sequence diversity, structural diversity, and length diversity. It is a non-mixed library with both natural and artificial advantages.

Peptide Innovation Alliance Leader Peptide Sheng Bio Founder & Chairman Wang Zhuyin

Dr. Chen Xiaoxin, co-founder and president of Zhongsheng Ruichuang, shared "Is the development of GLP-1 multi-target drugs a way to break the circle?" and proposed that long-term and multiple excitations are the mainstream research and development trends of GLP-RAs in the world, and introduced Zhongsheng Ruichuang's research and development achievements in the respiratory system and metabolism.

Zhongsheng Ruichuang Co-founder & President Chen Xiaoxin

The theme of Dr. Dou Liu, founder and CEO of Orly Bio, was "Innovation Platform for Oral Formulations of GLP-1 Drugs". Oral preparations are the main delivery method for small molecule drugs. Compared with injection preparations for the field of large molecule peptides, they have the advantages of simple administration, high compliance, and no direct damage to the skin or mucous membranes.

Dou Liu, founder and CEO of Orly Bio

Finally, Dr. Shen Weijun, director of the Translational Medicine Center of Shenzhen Bay Laboratory, hosted a roundtable meeting on "Innovation Acceleration Breakthrough Involution". The participating guests included Jiang Shibo, academician of the American Academy of Microbiology and director of the Institute of Pathogenic Microorganisms of Fudan University, Yao Zhiyong, founder of Jianyuan Pharmaceutical, Su Xianbin, professor of Nanjing University of Technology, Wang Qunjie, founder and chairman of Ajie Boya, Gan Jianhui, deputy general manager of Kangtai Biological, Ren Peigen, founder and chairman of Zhongke Xinjin, and Luo Hua, general manager of Chongqing Pu Nuowei. The seven roundtable guests expressed their views on the development issues of peptide drugs raised by Dr. Shen Weijun.

Wine Tasting and Hero Discussion

Drink a glass of wine and listen to the golden chapter.

When you are drunk and your heart is full, it is a good time to speak freely. The fragrance of flowers is elegant and the wine is clinking. Just like a wine has its old and new origins, GLP-1 drugs have made gradual progress and innovative breakthroughs in the tireless scientific research of biomedicine practitioners. Taking advantage of the romantic moment, industry leaders talked about the brilliant development of GLP-1 drugs.

Between the mountains and seas of South Guangdong, the exchanges between heroes have come to an end. Where will they meet next? Please wait and see!